Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND Treatment strategies to prevent ventricular tachycardia (VT) in patients with an implantable cardioverter-defibrillator (ICD) include antiarrhythmic drugs (AADs) and catheter ablation (CA). OBJECTIVE The purpose of this study was to systematically compare the efficacy of AADs and CA for the prevention of VT in patients with ICDs. METHODS Major databases were searched (October 2015) for randomized trials evaluating AADs or CA vs standard medical therapy to prevent VT in ICD patients. Primary outcome was the number of VT episodes leading to appropriate ICD interventions. RESULTS Eight trials (n = 2268, follow-up 15 6 months) evaluated AADs, and 6 trials (n = 427, follow-up 14 8 months) evaluated CA. A significant reduction in appropriate ICD interventions was found with both CA (odds ratio [OR] 0.45, 95% confidence interval [CI] 0.28-0.71, P = .001) and AADs (OR 0.66, 95% CI 0.44-0.97, P = .037), with no significant difference between the 2 treatment strategies. The benefit of AADs was driven by amiodarone and not confirmed with other AADs. A reduction of inappropriate ICD interventions was found with AADs (OR 0.30, P = .001) but not with CA. Both CA and AADs were not associated with decreased mortality over follow-up. Amiodarone appeared to increase the risk of death (OR 3.36, 95% CI 1.36-8.30, P = .009). CONCLUSION In patients with an ICD, both AADs (amiodarone) and CA reduce the risk of recurrent VT compared to control medical therapy, with no significant difference between the 2 treatments. AADs are also associated with a reduction of inappropriate ICD therapies. The significant reduction of recurrent VT episodes does not appear to result in a mortality benefit, with a potential for increased mortality with amiodarone.